MediJane Holdings to form Medical Advisory Committee
Longmont, CO / ACCESSWIRE / September 12, 2014 / MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or the "Company") to form Medical Advisory Committee.
MediJane is pleased to announce that it will be establishing a Medical Advisory Committee ("MAC"). MediJane Holdings and its technology licensor, Phoenix Bio Pharmaceuticals, have announced the planned development of an expanded panel of multidisciplinary physicians and health care professionals.
The newly-formed Medical Advisory Committee will serve the Company, providing their professional expertise in development of legalized medical cannabis (CBD, THC and CBG) products targeting specific health related conditions. The Medical Advisory Committee will include up to seven (7) members from the medical and scientific community with an expanded focus on legal medical cannabis care for conditions affecting pediatric neurology, oncology, and pain management.
"Creating a Medical Advisory Committee will enhance our established formulation and organic chemistry efforts and will provide us access to a broader scientific perspective with expanded medical experience. The MAC will also offer a wider spectrum of technical knowledge surrounding the development and acquisition of products supporting heath and wellness utilizing legalized cannabis. We are excited to form this committee and to utilize their expertise in expanding our custom formulations for cannabinoid treatments," stated Lewis "Spike" Humer, Chairman of MediJane.
MediJane is currently reviewing potential candidates for positions within the Medical Advisory Committee. We encourage additional qualified health care professionals seeking to provide their patients with alternative options for therapy to contact [email protected] for additional information.
Humer concluded, "Each day we hear of new case studies regarding the positive effects and potential impacts of medical cannabis and cannabinoid based treatments Search engines are increasingly populated with stories of the impact and promise of cannabinoid care. Personal stories of children being given new hope and increasing relief from juvenile seizures, examples of cancer patients seeing remarkable improvement in their condition or symptoms, emerging studies in the treatment of Parkinson's Disease and more appear in the continually in news. These breakthrough cases remind of our values-driven obligation to continue our mission.
The hundreds of thousands of registered patients remind us of the large-scale potential benefits of medical cannabis. The tens of thousands of people enrolling around the country to be part of medical marijuana state-registered programs supports our understanding of the increasing demand for access to cannabinoid care. We believe in the opportunity. We are committed to our mission to continue to develop and help make available new applications, products, and delivery systems for those seeking or needing them. This is why we started this journey. This is the reason we continually seek a path of progress in supporting health-enhancement, increased wellness, and helping people enhance their quality of life where we can."
About MediJane Holdings Inc. (MJMD)
MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical cannabis industry, including transdermal patches, capsules, sublingual sprays, oral strips, and other medical delivery systems as part of its strategic alliances with Phoenix Bio Pharmaceuticals (www.phoenixbiopharmaceuticals.com). With offices in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's products, including the innovative non-drowsy "Daytime Pain plus CBD" oral capsule, the CannaMist cannabinoid spray, and the MediStrip Relaxation oral strips, have been formulated for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. These smokeless alternatives provide accurate dosages and are part of MediJane's launch into the chronic pain management market. Any and all medically oriented statements have not been evaluated by the Food and Drug Administration.
For more information, visit www.medijane.co
Investor Contact:
MediJane Holdings Inc.
(855) 964-7233 (Toll-free)
E-mail: [email protected]
Website: www.medijane.co
Disclaimer/Safe Harbor: Some information in this MediJane press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MediJane's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in MediJane's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MediJane herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MediJane disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.
SOURCE: MediJane Holdings Inc.